Literature DB >> 7496915

Increased immunogenicity of inactivated influenza virus vaccine containing purified surface antigen compared with whole virus in elderly women.

D C Powers1.   

Abstract

Thirty-eight elderly female subjects (aged 80 +/- 7 years, mean +/- standard deviation) were randomized to immunization with trivalent inactivated influenza virus vaccine containing either purified surface antigen (n = 18) or whole virus (n = 20) components from A/Texas/36/91 (H1N1), A/Beijing/353/89 (H3N2), and B/Panama/45/90 strains. Humoral and cellular immune responses were assessed by measuring serum hemagglutination inhibition antibodies and cytotoxic T lymphocyte (CTL) activity at 0 and 3 weeks postvaccination. Serological responses to both of the type A vaccine strains following immunization with surface antigen vaccine (SAV) were significantly more frequent and greater in magnitude than those induced by whole-virus vaccine. Antibody responses to the B/Panama component were modest and did not differ significantly between the two vaccines. Persons given SAV, but not those given whole-virus vaccine, had a small but significant increase in mean percent specific lysis of influenza A (H1N1) virus-infected autologous targets by peripheral blood mononuclear cells which were stimulated in vitro with influenza A (H1N1) virus. The H1N1-stimulated cytotoxic effectors induced by SAV were CD8+ and were not cross-reactive against H3N2-infected targets. Influenza B virus-specific CTL responses were not observed with either vaccine. These results suggest that currently available subunit influenza virus vaccines may offer an advantage over inactivated whole-virus preparations for inducing humoral and cellular immune responses in the elderly, although the CTL response may be too limited to be of physiological significance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7496915      PMCID: PMC368189          DOI: 10.1128/cdli.1.1.16-20.1994

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  20 in total

Review 1.  Immunological principles and emerging strategies of vaccination for the elderly.

Authors:  D C Powers
Journal:  J Am Geriatr Soc       Date:  1992-01       Impact factor: 5.562

Review 2.  Determinants of immunity to influenza infection in man.

Authors:  C W Potter; J S Oxford
Journal:  Br Med Bull       Date:  1979-01       Impact factor: 4.291

3.  Antibody response after influenza immunization with various vaccine doses: a double-blind, placebo-controlled, multi-centre, dose-response study in elderly nursing-home residents and young volunteers.

Authors:  A M Palache; W E Beyer; M J Sprenger; N Masurel; S de Jonge; A Vardy; B Charpentier; J Noury; W C van Beek; R J Borst
Journal:  Vaccine       Date:  1993       Impact factor: 3.641

4.  Immunogenicity of influenza A/USSR (H1N1) subunit vaccine in unprimed young adults.

Authors:  A L Frank; R G Webster; W P Glezen; T R Cate
Journal:  J Med Virol       Date:  1981       Impact factor: 2.327

5.  The human cytotoxic T cell response to influenza A vaccination.

Authors:  A J McMichael; F Gotch; P Cullen; B Askonas; R G Webster
Journal:  Clin Exp Immunol       Date:  1981-02       Impact factor: 4.330

6.  Effect of age on cytotoxic T lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza virus vaccine.

Authors:  D C Powers; R B Belshe
Journal:  J Infect Dis       Date:  1993-03       Impact factor: 5.226

7.  The effect of influenza vaccination on IL2 production in healthy elderly: implications for current vaccination practices.

Authors:  J E McElhaney; G S Meneilly; B L Beattie; C D Helgason; S F Lee; R D Devine; R C Bleackley
Journal:  J Gerontol       Date:  1992-01

8.  Influenza A virus-specific cytotoxic T lymphocyte activity declines with advancing age.

Authors:  D C Powers
Journal:  J Am Geriatr Soc       Date:  1993-01       Impact factor: 5.562

9.  Summary of clinical trials of influenza virus vaccines in adults.

Authors:  P D Parkman; H E Hopps; S C Rastogi; H M Meyer
Journal:  J Infect Dis       Date:  1977-12       Impact factor: 5.226

10.  Immune interferon produced to high levels by antigenic stimulation of human lymphocytes with influenza virus.

Authors:  F A Ennis; A Meager
Journal:  J Exp Med       Date:  1981-11-01       Impact factor: 14.307

View more
  4 in total

1.  Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant.

Authors:  I Mbawuike; Y Zang; R B Couch
Journal:  Vaccine       Date:  2007-01-24       Impact factor: 3.641

2.  Influenza vaccination in older patients. Immunogenicity, epidemiology and available agents.

Authors:  H Glathe; W Lange
Journal:  Drugs Aging       Date:  1995-05       Impact factor: 3.923

3.  Comparison of Serology and Reactogenicity between Influenza Subunit Vaccines and Whole Virus or Split Vaccines: A Review and Meta-Analysis of the Literature.

Authors:  W E Beyer; A M Palache; A D Osterhaus
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

Review 4.  Quantitative review of antibody response to inactivated seasonal influenza vaccines.

Authors:  Jessica C Seidman; Stephanie A Richard; Cécile Viboud; Mark A Miller
Journal:  Influenza Other Respir Viruses       Date:  2011-06-13       Impact factor: 4.380

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.